Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, reports a 76% tumor reduction after participating in a clinical trial for the experimental drug daraxonrasib. Developed by Revolution Medicines, the therapy targets the RAS gene in pancreatic cancer, showing median survival of 13 months in trials compared to 6 months with standard chemotherapy.